Rhythm Pharmaceuticals officer proposes $1.32M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rhythm Pharmaceuticals, Inc. (RYTM) common shares are the subject of Pamela Cramer’s proposed sale of 11,406 shares, with an aggregate market value of $1,317,164.88 and an approximate sale date of August 11, 2026. Pamela Cramer is identified as an officer.
Remarks state that the securities to be sold were acquired upon vesting of restricted stock units from July 26, 2022, through July 26, 2024. The notice gives December 15, 2025, as the plan adoption or instruction date under its Rule 10b5-1 entry.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Restricted Stock Units financial
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.